Xtant Medical Inc. (XTNT)
Xtant Medical Statistics
Share Statistics
Xtant Medical has 139.07M shares outstanding. The number of shares has increased by 6.84% in one year.
Shares Outstanding | 139.07M |
Shares Change (YoY) | 6.84% |
Shares Change (QoQ) | 0.21% |
Owned by Institutions (%) | 71.57% |
Shares Floating | 51.58M |
Failed to Deliver (FTD) Shares | 2.82K |
FTD / Avg. Volume | 3.5% |
Short Selling Information
The latest short interest is 197.47K, so 0.14% of the outstanding shares have been sold short.
Short Interest | 197.47K |
Short % of Shares Out | 0.14% |
Short % of Float | 0.38% |
Short Ratio (days to cover) | 6.92 |
Valuation Ratios
The PE ratio is -3.6 and the forward PE ratio is -9.17. Xtant Medical's PEG ratio is 0.
PE Ratio | -3.6 |
Forward PE | -9.17 |
PS Ratio | 0.5 |
Forward PS | 0.5 |
PB Ratio | 1.38 |
P/FCF Ratio | -3.7 |
PEG Ratio | 0 |
Enterprise Valuation
Xtant Medical Inc. has an Enterprise Value (EV) of 152.21M.
EV / Earnings | -9.25 |
EV / Sales | 1.3 |
EV / EBITDA | -12.61 |
EV / EBIT | -12.61 |
EV / FCF | -9.51 |
Financial Position
The company has a current ratio of 2.35, with a Debt / Equity ratio of 0.3.
Current Ratio | 2.35 |
Quick Ratio | 1 |
Debt / Equity | 0.3 |
Total Debt / Capitalization | 23.15 |
Cash Flow / Debt | -0.92 |
Interest Coverage | -2.9 |
Financial Efficiency
Return on equity (ROE) is -0.38% and return on capital (ROIC) is -21.85%.
Return on Equity (ROE) | -0.38% |
Return on Assets (ROA) | -0.18% |
Return on Capital (ROIC) | -21.85% |
Revenue Per Employee | $540,400.92 |
Profits Per Employee | $-75,801.84 |
Employee Count | 217 |
Asset Turnover | 1.25 |
Inventory Turnover | 1.27 |
Taxes
Income Tax | 187K |
Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by -56.41% in the last 52 weeks. The beta is 0.41, so Xtant Medical's price volatility has been higher than the market average.
Beta | 0.41 |
52-Week Price Change | -56.41% |
50-Day Moving Average | 0.53 |
200-Day Moving Average | 0.57 |
Relative Strength Index (RSI) | 48.56 |
Average Volume (20 Days) | 80.39K |
Income Statement
In the last 12 months, Xtant Medical had revenue of 117.27M and earned -16.45M in profits. Earnings per share was -0.12.
Revenue | 117.27M |
Gross Profit | 68.22M |
Operating Income | -12.07M |
Net Income | -16.45M |
EBITDA | -12.07M |
EBIT | -12.07M |
Earnings Per Share (EPS) | -0.12 |
Balance Sheet
The company has 6.2M in cash and 12.94M in debt, giving a net cash position of -6.74M.
Cash & Cash Equivalents | 6.2M |
Total Debt | 12.94M |
Net Cash | -6.74M |
Retained Earnings | -259.46M |
Total Assets | 93.84M |
Working Capital | 38.53M |
Cash Flow
In the last 12 months, operating cash flow was -11.9M and capital expenditures -4.11M, giving a free cash flow of -16.01M.
Operating Cash Flow | -11.9M |
Capital Expenditures | -4.11M |
Free Cash Flow | -16.01M |
FCF Per Share | -0.12 |
Margins
Gross margin is 58.17%, with operating and profit margins of -10.3% and -14.03%.
Gross Margin | 58.17% |
Operating Margin | -10.3% |
Pretax Margin | -13.87% |
Profit Margin | -14.03% |
EBITDA Margin | -10.3% |
EBIT Margin | -10.3% |
FCF Margin | -13.65% |
Dividends & Yields
XTNT does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -23.53% |
FCF Yield | -22.59% |
Analyst Forecast
The average price target for XTNT is $3, which is 488.2% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $3 |
Price Target Difference | 488.2% |
Analyst Consensus | Strong Buy |
Analyst Count | 1 |
Stock Splits
The last stock split was on Feb 14, 2018. It was a backward split with a ratio of 1:12.
Last Split Date | Feb 14, 2018 |
Split Type | backward |
Split Ratio | 1:12 |
Scores
Altman Z-Score | -1.74 |
Piotroski F-Score | 2 |